600
Panorama Actual del Medicamento
REVISIÓN
Bibliografía
1. Sánchez MJ, Payer T, De Angelis R, Larrañaga N, Ca-
pocaccia R, Martínez C; CIBERESP Working Group.
Cancer incidence and mortality in Spain: estimates and
projections for the period 1981-2012.
Ann Oncol
. 2010;
21 Suppl 3: iii30-36. doi: 10.1093/annonc/mdq090.
2. Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-An-
tolín A, Villavicencio H, Cantalapiedra A, Pedrosa, E.
Registro nacional de cáncer de próstata 2010 en España.
Actas Urol Esp
. 2013; 37(1): 12-9.
3. World Health Organization (WHO).
GLOBOCAN 2008.
Estimated cancer Incidence, Mortality, Prevalence and Disa-
bility-adjusted life years (DALYs) Worldwide in 2008. http://
globocan.iarc.fr/factsheet.asp
4. American Cancer Society.
Cancer Facts & Figures 2013.
Atlanta: American Cancer Society; 2013. Disponible en:
-
gysurveilance/documents/document/acspc-036845.pdf
5. Chéchile GE.
Tratamiento farmacológico de los tumores
urogenitales. En: Terapéutica farmacológica de los tras-
tornos neoplásicos e inmunológicos. Consejo General de
Colegios Oficiales de Farmacéuticos. Madrid; 2011. p. 265-
294.
6. Johnson D.
Gleason 7: ¿una nueva categoría de riesgo?
The ProstateNet.
/
gleason7.html
7. Discacciati A, Orsini N, Andersson SO, Andrén O, Jo-
hansson JE, Mantzoros CS, Wolk A.
Coffee consumption
and risk of localized, advanced and fatal prostate cancer: a
population-based prospective study.
Ann Oncol
. 2013 Mar
18 [Epub ahead of print]. doi: 10.1093/annonc/mdt105
8. Heidenreich A (chair), Bastian PJ, Bellmunt J, Bolla M,
Joniau S, Mason MD, Matveev V, Mottet N, van der
Kwast, Wiegel T, Zattoni F.
Guidelines on prostate can-
cer.
European Association of Urology
2013.
.
uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf
9. Carter HB, Kettermann AE, Ferrucci L, Landis P, Trock
BJ, Metter EJ.
Prostate specific antigen testing among the
elderly; when to stop?
J Urol
2008; 174(2)( Suppl 1):600
abstract #1751.
10. Thompson IM, Pauler DK, Goodman PJ, Tangen CM,
Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman
SM,Crawford ED, Crowley JJ, Coltman CA Jr.
Preva-
lence of prostate cancer among men with a prostate-spe-
cific antigen level < or =4.0 ng per milliliter.
N Engl J Med
2004; 350(22): 2239-46.
11. D’Amico AV, Crook JM, Beard CJ, DeWeese TL,
Hurwitz M, Kaplan ID.
Radiation therapy for pros-
tate cancer. In: Wein AJ, Kavoussi LR, Novick AC, et al.,
eds. Campbell-Walsh Urology. 10th ed. Philadelphia, PA:
Elsevier Saunders; 2011: chap 104.
12. Cuéllar S.
Abiraterona (Zytiga®).
Panorama Actual Med.
2012; 36(351): 154-63.
13. Ryan CJ, Smith MR, de Bono JS, et al; the COU-AA-302
Investigators.
Abiraterone in Metastatic Prostate Cancer
without Previous Chemotherapy.
N Engl J Med
. 2013; 368:
138-48. DOI: 10.1056/NEJMoa1209096
14. Osanto S, Van Poppel H.
Emerging novel therapies for
advanced prostate cancer.
Ther Adv Urol
. 2012; 4(1): 3-12.
15. Fourcade R, Benedict A, Black L, Stokes M, Alcaraz A,
Castro R.
Treatment costs of prostate cancer in the first
year after diagnosis: a short-term cost of illness study for
France, Germany, Italy, Spain, and the UK.
BJUI
. 2009; 105:
49-56.
16. Abascal JM.
Estudio de la osteoporosis inducida por la de-
privación androgénica en pacientes con cáncer de próstata.
Tesis doctoral, junio
2010
.
/
html_bura/ficha/params/id/38614731.html
17. Cuéllar S.
Denosumab (Prolia®).
Panorama Actual Med.
2011; 35(347): 815-24.
18. Smith MR, Egerdie B, Hernández Toriz N, Feldman R,
Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C,
Kupic A, Leder BZ, Goessl C; Denosumab HALT Pros-
tate Cancer Study Group.
Denosumab in men receiving
androgen-deprivation therapy for prostate cancer.
N Engl J
Med
. 2009; 361(8): 745-55.
19. Cuéllar S.
Cabazitaxel (Jevtana®), en cáncer de próstata.
Panorama Actual Med.
2011; 35(347): 830-6.
20. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Ma-
chiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ,
Shen L, Roessner M, Gupta S, Sartor AO; TROPIC In-
vestigators.
Prednisone plus cabazitaxel or mitoxantrone
for metastatic castration-resistant prostate cancer progres-
sing after docetaxel treatment: a randomised open-label
trial.
Lancet
. 2010; 376(9747): 1147-54.
21. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North
S, Chu L, et al; COU-AA-301 Investigators.
Abiraterone
and increased survival in metastatic prostate cancer.
N Engl
J Med
. 2011; 364(21): 1995-2005.
22. Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon
S et al.
Therapeutic options in docetaxel-refractory metas-
tatic castration-resistant prostate cancer: A cost-effective-
ness analysis.
PLOS ONE
. 2013; 8(5): e64275.
23. European Medicines Agency.
EU Clinical Trials Register.
